» Articles » PMID: 10768680

Antimicrobial Use in Defined Populations of Infants and Young Children

Overview
Specialty Pediatrics
Date 2000 Apr 18
PMID 10768680
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Antimicrobial overprescribing contributes to bacterial resistance, but data on use in infants and young children are limited.

Objectives: To assess antimicrobial use in a defined population of infants and young children and to determine diagnosis-specific prescribing rates for common infections.

Design And Setting: Retrospective cohort study of children served by 44 practices affiliated with 2 managed care organizations.

Patients: Children aged 3 months to 72 months enrolled in either health plan between September 1, 1994, and August 31, 1996.

Analysis: Rates of antimicrobial use were calculated as the number of pharmacy dispensings divided by the number of person-years of observation contributed to the cohort in 2 age groups (3 to <36 months and 36 to <72 months). Other outcomes included the distribution of diagnoses associated with antimicrobial dispensing and population-based rates of diagnosis of common acute respiratory tract illnesses.

Results: A total of 46477 children contributed 59710 person-years of observation across the 2 health plans. Rates of antimicrobial dispensing for children aged 3 to 36 months were 3.2 and 2.1 dispensings per person-year in the 2 populations. A substantial fraction of younger children (35% in population A and 23% in population B) received 4 or more antimicrobial prescriptions in a single year. For children aged 36 to 72 months, the dispensing rates for the 2 populations were 2.0 and 1.5 antimicrobials per person-year. We found significant differences in rates between the populations studied and a decrease in use at all sites from 1995 to 1996. The diagnosis of otitis media accounted for 56% of antimicrobial drugs dispensed to children aged 3 to 36 months and 40% of those dispensed to children aged 36 to 72 months. Antimicrobial prescribing for colds and upper respiratory tract infections, bronchitis, and sinusitis was less frequent than previously reported but accounted for 10% to 14% of antimicrobial drugs dispensed.

Conclusions: In these populations, otitis media accounted for the largest number of antimicrobial agents dispensed to children younger than 6 years. Clearly inappropriate indications such as cold, upper respiratory tract infection, and bronchitis accounted for smaller fractions of antimicrobial use but may be most amenable to change. However, interventions that encourage use of strict criteria for diagnosis and treatment of otitis media will likely have the greatest impact on overall antimicrobial exposure. Monitoring defined populations longitudinally will allow assessment of the effectiveness of such national and local initiatives.

Citing Articles

Lactobacillus acidophilus VB1 co-aggregates and inhibits biofilm formation of chronic otitis media-associated pathogens.

Algburi A, Jassim S, Popov I, Weeks R, Chikindas M Braz J Microbiol. 2024; 55(3):2581-2592.

PMID: 38789905 PMC: 11405553. DOI: 10.1007/s42770-024-01363-5.


Antibiotics Not Associated with Shorter Duration or Reduced Severity of Acute Lower Respiratory Tract Infection.

Merenstein D, Barrett B, Ebell M J Gen Intern Med. 2024; 39(10):1887-1894.

PMID: 38619737 PMC: 11282002. DOI: 10.1007/s11606-024-08758-y.


Development and Validation of an Automated Classifier to Diagnose Acute Otitis Media in Children.

Shaikh N, Conway S, Kovacevic J, Condessa F, Shope T, Haralam M JAMA Pediatr. 2024; 178(4):401-407.

PMID: 38436941 PMC: 10985552. DOI: 10.1001/jamapediatrics.2024.0011.


Parents' experiences caring for children with acute otitis media: a qualitative analysis.

Lee M, Kavalieratos D, Alberty A, Groff D, Haralam M, Shaikh N BMC Prim Care. 2022; 23(1):123.

PMID: 35606702 PMC: 9128094. DOI: 10.1186/s12875-022-01737-4.


Evaluation of Cefuroxime Axetil-Loaded Bioadhesive Nanoparticles to Treat Induced Otitis Media.

Lin H, Jia Y, Kong X, Wang S, Liu X, Liu Y Front Bioeng Biotechnol. 2022; 10:884797.

PMID: 35573224 PMC: 9099258. DOI: 10.3389/fbioe.2022.884797.